Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $0.50 on Tuesday. The stock has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $2.93. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp bought a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals in the 2nd quarter valued at $65,000. Fidelis Capital Partners LLC purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $71,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Eagle Pharmaceuticals in the second quarter worth $76,000. Finally, Creative Planning purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter worth $59,000. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.